poisar

Stocks · News reference

Werewolf Therapeutics shares are trading higher after the company announced a merger with Ambros Therapeutics. The companies secured commitments for an oversubscribed concurrent private placement of $150 million from a syndicate of leading healthcare-dedicated investor.

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

HOWL
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Brodsky & Smith

    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)

    Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Personalis (acquired by Tempus AI for $16.25/share), Werewolf Therapeutics (acquired by Ambros Therapeutics), Beazer Homes (acquired by Dream Finders Homes for $33.50/share), and MarketAxess Holdings (acquired by Intercontinental Exchange for $167/share).

    PSNLHOWLBZHMKTX